Avalo Therapeutics, Inc. (AVTX) · Nov 5, 2026 · Earnings
Beat — EPS -$0.34 vs approximately -$0.59 consensus
Avalo’s third-quarter earnings beat the loss consensus, while its Phase 3 and AVTX-010 timelines remain largely unchanged.
Avalo is a cash-rich, clinical-stage biotech moving its lead drug abdakibart from the positive Phase 2 LOTUS readout toward a planned Phase 3 program in hidradenitis suppurativa, while building a second IL-1β asset, AVTX-010. That direction was already established by the May clinical readout, the May financing, and the second-quarter update, which set Phase 3 and AVTX-010 milestones for the first half of 2027.
The quarterly beat is real, but not the main business signal. GAAP loss per share was $0.34, versus a published consensus of roughly $0.59 per share, making this a clear EPS beat. The improvement was helped by lower derivative-liability expense and higher interest income rather than by operating progress, so it carries less strategic weight than a clinical or regulatory update.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| R&D expense (Operating expenses) | $15.0M | $13.6M | |
| G&A expense (Operating expenses) | $8.4M | $5.6M | |
| Net loss (Income Statement) | $18.9M | $30.6M | |
| Loss per share (Income Statement) | $0.34 | $2.19 | ~$0.59 loss |
| Cash, equivalents and investments (Financial Highlights) | $462.8M |
The underlying spending picture is moving toward pivotal development. R&D rose by $1.4 million as manufacturing work for AVTX-010 and abdakibart increased, while G&A rose by $2.8 million largely from compensation. That is negative on near-term expenses, but consistent with a company preparing its lead program and next-generation antibody for the next development stage.
Liquidity removes the immediate financing question, not the clinical risk. Avalo ended September with $462.8 million in cash, cash equivalents and investments after using $49.2 million in operating cash during the first nine months, and management still expects funding into 2029. That gives the company room to execute the planned Phase 3 program without an obvious near-term capital raise, but it does not add evidence that LOTUS will translate into registrational success.
The clinical and regulatory timetable is confirmation, not acceleration. Avalo still expects FDA feedback on the proposed abdakibart development plan by year-end 2026, plans to start Phase 3 in the first half of 2027, and anticipates an AVTX-010 IND submission in the first half of 2027. Those milestones were already public in the second-quarter release, so this filing mainly preserves the existing story rather than materially improving it. 〔0〕
Bottom line: Avalo delivered a narrow earnings beat and remains well funded, but the filing does not change the core biotech story. The important value-creating milestones are still ahead: FDA feedback and Phase 3 execution, not this quarter’s accounting-driven EPS improvement.
FDA feedback on abdakibart development plan by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!